Janneke R. Zinkstok

Janneke R. Zinkstok

Auto-generated profile, based on publicly available information

Janneke R. Zinkstok

Department of Psychiatry Radboud University Medical Center Nijmegen The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in The Lancet Psychiatry
Verified
Journal Article
Closed access
JZJanneke R Zinkstok
Janneke R Zinkstok
EBErik Boot
Erik Boot
ABAnne S Bassett
Anne S Bassett
NHNoboru Hiroi
Noboru Hiroi
NBNancy J Butcher
Nancy J Butcher
TATherese A M J van Amelsvoort
Therese A M J van Amelsvoort

11 October 2022 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
JPJusto Pinzón-Espinosa
Justo Pinzón-Espinosa
MHMarte van der Horst
Marte van der Horst
JZJanneke Zinkstok
Janneke Zinkstok
JAJehannine Austin
Jehannine Austin
CACora Aalfs
Cora Aalfs
JLJurjen Luykx
Jurjen Luykx
Genetic testing has evolved rapidly over recent years and new developments have the potential to provide insights that could improve the ability to diagnose, treat, and prevent diseases. Information obtained through genetic testing has proven useful in other specialties, such as cardiology and oncology. Nonetheless, a range of barriers impedes techniques, such as whole-exome or whole-genome sequencing, pharmacogenomics, and polygenic risk scoring, from being implemented in psychiatric practice. These barriers may be procedural (e.g., limitations in extrapolating results to the individual level), economic (e.g., perceived relatively elevated costs precluding insurance coverage), or related to clinicians’ knowledge, attitudes, and practices (e.g., perceived unfavorable cost-effectiveness, insufficient understanding of probability statistics, and concerns regarding genetic counseling). Additionally, several ethical concerns may arise (e.g., increased stigma and discrimination through exclusion from health insurance). Here, we provide an overview of potential barriers for the implementation of genetic testing in psychiatry, as well as an in-depth discussion of strategies to address these challenges.

24 February 2021 in Current Psychiatry Reports
Verified
Journal Article
Open access
PDF file
AFAnia M. Fiksinski
Ania M. Fiksinski
MSMaude Schneider
Maude Schneider
JZJanneke Zinkstok
Janneke Zinkstok
DBDanielle Baribeau
Danielle Baribeau
SCSamuel J. R. A. Chawner
Samuel J. R. A. Chawner
JVJacob Vorstman
Jacob Vorstman
Purpose of Review: The 22q11.2 deletion syndrome (22q11DS) is associated with a broad spectrum of neurodevelopmental phenotypes and is the strongest known single genetic risk factor for schizophrenia. Compared to other rare structural pathogenic genetic variants, 22q11DS is relatively common and one of the most extensively studied. This review provides a state-of-the-art overview of current insights regarding associated neurodevelopmental phenotypes and potential implications for 22q11DS and beyond.Recent Findings: We will first discuss recent findings with respect to neurodevelopmental phenotypic expression associated with 22q11DS, including psychotic disorders, intellectual functioning, autism spectrum disorders, as well as their interactions. Second, we will address considerations that are important in interpreting these data and propose potential implications for both the clinical care for and the empirical study of individuals with 22q11DS. Third, we will highlight variable penetrance and pleiotropy with respect to neurodevelopmental phenotypes in 22q11DS. We will discuss how these phenomena are consistently observed in the context of virtually all rare pathogenic variants and that they pose substantial challenges from both a clinical and a research perspective.Summary: We outline how 22q11DS could be viewed as a genetic model for studying neurodevelopmental phenotypes. In addition, we propose that 22q11DS research can help elucidate mechanisms underlying variable expression and pleiotropy of neurodevelopmental phenotypes, insights that are likely relevant for 22q11DS and beyond, including for individuals with other rare pathogenic genetic variants and for individuals with idiopathic neurodevelopmental conditions.

1 February 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
EEE. Eeltink
E. Eeltink
MHM.Z. van der Horst
M.Z. van der Horst
JZJ.R. Zinkstok
J.R. Zinkstok
CAC.M. Aalfs
C.M. Aalfs
JLJurjen Luykx
Jurjen Luykx
Polygenic risk scores (PRS) may aid in the identification of individuals at-risk for psychiatric disorders, treatment optimization, and increase in prognostic accuracy. PRS may also add significant value to genetic counseling. Thus far, integration of PRSs in genetic counseling sessions remains problematic because of uncertainties in risk prediction and other concerns. Here, we review the current utility of PRSs in the context of clinical psychiatry. By comprehensively appraising the literature in other fields of medicine including breast cancer, Alzheimer's Disease, and cardiovascular disease, we outline several lessons learned that could be applied to future studies and may thus benefit the incorporation of PRS in psychiatric genetic counseling. These include integrating PRS with environmental factors (e.g. lifestyle), setting up large-scale studies, and applying reproducible methods allowing for cross-validation between cohorts. We conclude that psychiatry may benefit from experiences in these fields. PRS may in future have a role in genetic counseling in clinical psychiatric practice, by advancing prevention strategies and treatment decision-making, thus promoting quality of life for (potentially) affected individuals.

31 October 2022 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
ESEmma N.M.M. von Scheibler
Emma N.M.M. von Scheibler
AEAgnies M. Van Eeghen
Agnies M. Van Eeghen
TKTom J. de Koning
Tom J. de Koning
MKMark L. Kuijf
Mark L. Kuijf
JZJanneke R. Zinkstok
Janneke R. Zinkstok
EBErik Boot
Erik Boot
Background: With advances in clinical genetic testing, associations between genetic neurodevelopmental disorders and parkinsonism are increasingly recognized. In this review, we aimed to provide a comprehensive overview of reports on parkinsonism in genetic neurodevelopmental disorders and summarize findings related to genetic diagnosis, clinical features and proposed disease mechanisms.Methods: A systematic literature review was conducted in PubMed and Embase on June 15, 2021. Search terms for parkinsonism and genetic neurodevelopmental disorders, using generic terms and the Human Phenotype Ontology, were combined. Study characteristics and descriptive data were extracted from the articles using a modified version of the Cochrane Consumers and Communication Review Group's data extraction template. The protocol was registered in PROSPERO (CRD42020191035).Results: The literature search yielded 208 reports for data‐extraction, describing 69 genetic disorders in 422 patients. The five most reported from most to least frequent were: 22q11.2 deletion syndrome, beta‐propeller protein‐associated neurodegeneration, Down syndrome, cerebrotendinous xanthomatosis, and Rett syndrome. Notable findings were an almost equal male to female ratio, an early median age of motor onset (26 years old) and rigidity being more common than rest tremor. Results of dopaminergic imaging and response to antiparkinsonian medication often supported the neurodegenerative nature of parkinsonism. Moreover, neuropathology results showed neuronal loss in the majority of cases. Proposed disease mechanisms included aberrant mitochondrial function and disruptions in neurotransmitter metabolism, endosomal trafficking, and the autophagic‐lysosomal and ubiquitin‐proteasome system.Conclusion: Parkinsonism has been reported in many GNDs. Findings from this study may provide clues for further research and improve management of patients with GNDs and/or parkinsonism.

4 April 2011 in Synapse
Verified
Journal Article
Closed access
PDF file
EBErik Boot
Erik Boot
JBJan Booij
Jan Booij
JZJanneke R. Zinkstok
Janneke R. Zinkstok
FBFrank Baas
Frank Baas
ASAnn Swillen
Ann Swillen
TAThérèse A. Van Amelsvoort
Thérèse A. Van Amelsvoort